Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
Status:
Withdrawn
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label study designed to evaluate the safety and efficacy of the selective
inhibitor of nuclear export (SINE) compound, Selinexor given orally to patients with
transfusion-dependent, EPO-refractory lower-risk MDS (Low risk and Intermediate-1 as defined
by IPSS).